Allison Montalbano
Pediatric Critical Care Medicine · Houston, TXNPI 1720751415
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 28.2% of the total. Reporting peaked in 2022 at $1,334 and has fallen 75.3% since, to $330 in 2025. Among pediatric critical care medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$706
- Lilly USA, LLC$352
- AbbVie$265
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$170
- AstraZeneca$169
- Cequr Corporation$121
- plus $719 from 18 others
What the payments were for
- Food & beverage$2,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $706 |
| Lilly USA, LLC | 21 | $352 |
| AbbVie | 8 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $170 |
| AstraZeneca | 10 | $169 |
| Cequr Corporation | 1 | $121 |
| Bayer | 5 | $119 |
| GSK | 7 | $99 |
| Pfizer | 4 | $76 |
| Novartis | 4 | $63 |
| Mannkind Corporation | 2 | $42 |
| Astellas Pharma US Inc | 2 | $40 |
| Tandem Diabetes Care, Inc. | 1 | $32 |
| Dexcom, Inc. | 1 | $32 |
| Merck | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Radius Health, Inc. | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $20 |
| Octapharma USA, Inc. | 1 | $17 |
| Amgen | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Creon$125
- CeQur Simplicity$121
- Ozempic$102
- XIFAXAN$101
How this compares
$2,501 in reported general payments places this provider in the 90th percentile of 165 pediatric critical care medicine providers in Texas.
See all pediatric critical care medicine providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 36 | $244 |
| Atorvastatin Calcium | 18 | $81 |
| Amlodipine Besylate | 12 | $67 |
| Lisinopril | 14 | $63 |
Paid to pharmacies, not to this prescriber.
Other pediatric critical care medicine in Houston
- Sebastian TumeHouston$20K
- Justin ElhoffHouston$13K
- Saul FloresHouston$12K
- Ayse Akcan ArikanHouston$8K
- Hunter HamiltonHouston$4K
- Trung NguyenHouston$3K
- Marc AndersHouston$2K
- Kenneth BradyHouston$2K
- Javier LasaHouston$1K
- Khayri ShalhoubHouston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.